About Juvenescence
Juvenescence is a Healthcare company based in Dublin (Ireland) founded in 2017 by Greg Bailey. Juvenescence has raised $289.89 million across 7 funding rounds from investors including M42, Fastforward Innovations and IDO Investments. Juvenescence has completed 1 acquisition, including Ro5. Its chief executive, as recorded, is Greg Bailey. Juvenescence offers products and services including Aging Medicines and AI-Enabled R&D Tools. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.
- Headquarters Dublin, Ireland
- Founders Greg Bailey
- SectorsHealthcare
- Website juvlabs.com
- Social LinkedIn X Facebook
Products & Services of Juvenescence
Juvenescence offers a comprehensive portfolio of products and services, including Aging Medicines and AI-Enabled R&D Tools.
Medicines targeting core aging processes for disease prevention.
Tools integrating AI to design and accelerate drug development.
Funding Insights of Juvenescence
Juvenescence has successfully raised a total of $289.89M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $76 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $289.89M
- Total Rounds 7
- Last Round Series B — $76M
- First Round $2.51M
(Dec 2017)
- Investors Count 9
All 7 funding rounds of Juvenescence with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $76M | Series B | – | – | |
| Sep 2019 | Series B | – | IDO Investments | – | |
| Aug 2019 | $100M | Series B | – | Grok Ventures, Ipgl | – |
| Jan 2019 | $46M | Series B | – | – | – |
| Jun 2018 | $53.08M | Series A | – | Fastforward Innovations | – |
| Jan 2018 | $12.3M | Seed | – | Foresite Capital, Apeiron Investment Group | |
| Dec 2017 | $2.51M | Seed | – | – | – |
8 investors in total: 7 institutional and 1 angel.
Investors in Juvenescence
Juvenescence has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include M42, Fastforward Innovations and IDO Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups are targeted for investments by this venture capital firm. | ido.om | Muscat, Oman | ||
Early-late stage tech-focused venture capital firm | grok.ventures | Surry Hills, Australia | ||
Tech & life Science focused early stage VC firm investing in North America & Europe | 2006 | fstfwd.co | Saint Peter Port, Guernsey | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital firm backed by Christian Angermayer | apeiron-investments.com | Sliema, Malta | ||
| ipgl.co.in | ||||
Provider of integrated healthcare solutions for diagnosis purpose | 2023 | m42.ae | Abu Dhabi, United Arab Emirates | |
KH Karim Hakimzadeh | unknown_a1f753c18d1f403cb |
Investor details for Juvenescence
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Juvenescence
23 people are tracked at Juvenescence (11 in leadership, 7 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Greg Bailey | Co-Founder & CEO | Leadership |
Tod Henjes | President, JuvLife | Leadership |
Sarah Flatters | Director Of Biomedical Data Science | Leadership |
Richard Marshall | CEO | Leadership |
David Gill | CFO | Leadership |
Gerson Montenegro | Chief Operating Officer - COO | Leadership |
Paul Russell | Chief Development Officer | Leadership |
Martin Ducker | Chief Science Officer, JuvLife | Leadership |
Kersten Small | Director Research And Early Development | Leadership |
Alexander Pickett | Managing Director | Leadership |
Steve Felstead | Head of Development Projects | Leadership |
Denham Eke | Board Member | Board & advisors |
Jean-Christophe Renondin | Board Member | Board & advisors |
Pedro de Noronha Pissarra | Scientific Advisor | Board & advisors |
Michael Hufford | Scientific Advisor | Board & advisors |
Brianna Stubbs | Scientific Advisor | Board & advisors |
Jim Mellon | Deputy Chairman & Co-Founder | Board & advisors |
Declan Doogan | Board Member & Co-Founder | Board & advisors |
Caitriona Collins ACA | Group Finance Manager | Team |
Laurie McFetridge, CMA | US Financial Controller | Team |
3 more people are available in the full profile.
Complete people profiles for Juvenescence
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Juvenescence
Juvenescence has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ro5.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based drug discovery management tool is provided for researchers. | ro5.ai | London, United Kingdom | 2018 | Apr 2025 | •••• |
Complete acquisition details for Juvenescence
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Juvenescence
4 dated milestones of Juvenescence across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Juvenescence is founded.
- Funding First funding round of $2.5M.
- Acquisition Acquires Ro5.
- Funding Latest funding round, Series B, of $76.0M.
Web traffic of Juvenescence
The website of Juvenescence (juvlabs.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▲ 8.9% vs previous month
Websites whose visitors overlap most with Juvenescence. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| longevity.technology | 100% | 171.9K | #251,646 | View details | |
thepharmaletter.com | thepharmaletter.com | 60% | #486,864 | – | |
| pharmaceutical-technology.com | 60% | #316,052 | View details | ||
masterinvestor.co.uk | masterinvestor.co.uk | 31% | #4,153,759 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Juvenescence
Complete news archive for Juvenescence
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Juvenescence
Juvenescence was founded in 2017.
Juvenescence is headquartered in Dublin, Ireland.
Greg Bailey is the CEO of Juvenescence, as recorded in our data. They have also founded this company.
Juvenescence is a funded company, having raised a total of $289.89M across 7 funding rounds to date. The company's 1st funding round was a Seed of $2.51M, raised on Dec 2017.
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.
Juvenescence offers Aging Medicines and AI-Enabled R&D Tools.
Juvenescence has made 1 acquisition, including Ro5.
Juvenescence has 8 investors. Key investors include M42, Fastforward Innovations, IDO Investments, Grok Ventures, and Ipgl.